Allovir Inc (ALVR)

$9.81 +0.15 (1.55%)
Market Cap 49.48M
Revenue (ttm) 0.00
Net Income (ttm) -58.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 9,400
Avg Vol 23,718
Day's Range N/A - N/A
Shares Out 5.04M
Stochastic %K 61%
Beta 0.63
Analysts Strong Buy
Price Target $34.48
11thestate
11thestate Oct. 22 at 12:10 PM
$ALVR has agreed to a $1M settlement to resolve claims that it misled investors about the effectiveness and prospects of its lead product, Posoleucel. Who’s eligible? Anyone who purchased $ALVR shares between January 11, 2023, and December 21, 2023. Do I need to sell my shares to qualify? No — you are eligible whether you sold your shares or still hold them. How much is the payout? The payout per share is $0.03 — but if only ~25% of eligible investors file, the effective payout could increase to $0.12. Can I still file? Yes — claims are currently being accepted, including late claims (claim deadline pending court approval). When do payouts happen? Typically within 8–12 months after court approval of the settlement. To file your claim: https://11th.com/cases/allovir-investor-settlement?utm_source=stocktwits&utm_medium=referral&utm_campaign=faq&utm_content=10222025_1
0 · Reply
11thestate
11thestate Oct. 14 at 11:52 AM
$ALVR has agreed to a $1.X million settlement to resolve claims that it misled investors about the effectiveness of its lead drug candidate, Posoleucel, and the likelihood of success for its Phase 3 trials. Who’s eligible? Anyone who purchased $ALVR shares between January 11, 2023 and December 21, 2023. Do I need to sell my shares to qualify? No — you are eligible whether you sold your shares or still hold them. How much is the payout? The payout per share is $0.03 — but if only ~25% of eligible investors file, the effective payout could increase to $0.12. Can I still file? Yes — claims are currently being accepted. When do payouts happen? Typically within 8–12 months after court approval of the settlement. To file your claim: https://11th.com/cases/allovir-investor-settlement?utm_source=stocktwits&utm_medium=referral&utm_campaign=faq&utm_content=10142025_1
0 · Reply
GridDrift_33
GridDrift_33 Oct. 2 at 3:15 PM
$ALVR NXXT at $1.94 with P S 4.9x lining for rerate to $5.5 once margins flip and EPS prints
0 · Reply
11thestate
11thestate Sep. 24 at 12:52 PM
$ALVR has agreed to settle with investors by paying $1 million to resolve claims that it misled them about the effectiveness of its lead product, Posoleucel. Who’s eligible? Anyone who purchased $ALVR shares between January 11, 2023 and December 21, 2023. Do I need to sell my shares to qualify? No — you are eligible whether you sold your shares or still hold them. How much is the payout? The payout per share is $0.03 — but if only ~25% of eligible investors file, the effective payout could increase to $0.12. Can I still file? Yes — late claims are currently being accepted. When do payouts happen? Typically within 8–12 months after court approval of the settlement. To file your claim: https://11th.com/cases/allovir-investor-settlement?utm_source=stocktwits&utm_medium=referral&utm_campaign=faq&utm_content=09242025_1
0 · Reply
topstockalerts
topstockalerts Sep. 16 at 6:48 PM
$ALVR setting up nicely.. 👀
0 · Reply
11thestate
11thestate Sep. 11 at 10:36 PM
$ALVR has agreed to settle with investors by paying $1 million to resolve claims that it misled them about the effectiveness of its lead product, Posoleucel. Who’s eligible? Anyone who purchased $ALVR shares between January 11, 2023 and December 21, 2023. Do I need to sell my shares to qualify? No — you are eligible whether you sold your shares or still hold them. How much is the payout? The payout per share is $0.03 — but if only ~25% of eligible investors file, the effective payout could increase to $0.12. Can I still file? Yes — late claims are currently being accepted. When do payouts happen? Typically within 8–12 months after court approval of the settlement. To file your claim: https://11th.com/cases/allovir-investor-settlement?utm_source=stocktwits&utm_medium=referral&utm_campaign=faq&utm_content=09112025_1
0 · Reply
11thestate
11thestate Sep. 4 at 2:39 AM
$ALVR investors, if you follow us, you already knew about it. This is the good news you needed about $ALVR today. Go check it out: https://11th.com/cases/allovir-investor-settlement?utm_source=stocktwits&utm_medium=referral&utm_campaign=stlm&utm_content=09032025_1 #AlloVir #ALVR
0 · Reply
11thestate
11thestate Aug. 26 at 3:55 AM
$ALVR has reached a $1 million settlement with investors to resolve claims that it misled them about the effectiveness of its lead product, Posoleucel. Who’s eligible? Anyone who purchased $ALVR shares between January 11, 2023, and December 21, 2023. Do I need to sell my shares to qualify? No — you are eligible whether you sold your shares or still hold them. How much is the payout? The payout per share is $0.03 — but if only ~25% of eligible investors file, the effective payout could increase to $0.12 per share. Can I still file? Yes — claims are currently being accepted. When do payouts happen? Typically within 8–12 months after court approval of the settlement. To file your claim: https://11th.com/cases/allovir-investor-settlement?utm_source=stocktwits&utm_medium=referral&utm_campaign=faq&utm_content=08262025_1
0 · Reply
11thestate
11thestate Aug. 15 at 4:45 AM
#AlloVir has reached a $1M settlement with $ALVR investors over claims that it misled them about the effectiveness of its lead product, Posoleucel. 📅 Class Period: Jan 11, 2023 – Dec 21, 2023 🗓️ Claim Deadline: Aug 19, 2025 If you purchased $ALVR during this period, you may be eligible for compensation here: https://11th.com/cases/allovir-investor-settlement?utm_source=stocktwits&utm_medium=referral&utm_campaign=ddl&utm_content=08152025_7
0 · Reply
11thestate
11thestate Aug. 13 at 10:43 AM
#AlloVir has reached a $1M settlement with $ALVR investors over claims it misled them about the effectiveness of its lead product, Posoleucel. 📅 Class Period: Jan 11, 2023 – Dec 21, 2023 🗓️ Claim Deadline: Aug 19, 2025 If you purchased $ALVR during this period, you may be eligible for compensation here: https://11th.com/cases/allovir-investor-settlement?utm_source=stocktwits&utm_medium=referral&utm_campaign=ddl&utm_content=08122025_1
0 · Reply
Latest News on ALVR
ALLOVIR INVESTIGATION: Bragar Eagel & Squire, P.C. Continues Investigation into AlloVir, Inc. on Behalf of Long-Term Stockholders

Oct 16, 2025, 5:14 PM EDT - 9 days ago

ALLOVIR INVESTIGATION: Bragar Eagel & Squire, P.C. Continues Investigation into AlloVir, Inc. on Behalf of Long-Term Stockholders

Bronstein, Gewirtz & Grossman, LLC Is Investigating AlloVir Inc. (ALVR) And Encourages Investors to Connect

Jun 17, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating AlloVir Inc. (ALVR) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages AlloVir Inc. (ALVR) Stockholders to Inquire about Securities Investigation

Jun 15, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages AlloVir Inc. (ALVR) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against AlloVir Inc. (ALVR) and Encourages Investors to Learn More About the Investigation

Jun 12, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against AlloVir Inc. (ALVR) and Encourages Investors to Learn More About the Investigation

AlloVir Inc. (ALVR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jun 10, 2025, 10:00 AM EDT - 4 months ago

AlloVir Inc. (ALVR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against AlloVir Inc. (ALVR) And Encourages Stockholders to Reach Out

Jun 8, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against AlloVir Inc. (ALVR) And Encourages Stockholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Is Investigating AlloVir Inc. (ALVR) And Encourages Stockholders to Connect

Jun 5, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating AlloVir Inc. (ALVR) And Encourages Stockholders to Connect

AlloVir Inc. (ALVR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Jun 3, 2025, 10:00 AM EDT - 5 months ago

AlloVir Inc. (ALVR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against AlloVir Inc. (ALVR) and Encourages Stockholders to Learn More About the Investigation

Jun 1, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against AlloVir Inc. (ALVR) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages AlloVir Inc. (ALVR) Investors to Inquire about Securities Investigation

May 29, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages AlloVir Inc. (ALVR) Investors to Inquire about Securities Investigation

Kalaris Announces Closing of Merger with AlloVir

Mar 18, 2025, 4:21 PM EDT - 7 months ago

Kalaris Announces Closing of Merger with AlloVir

KLRS

Kalaris and AlloVir Announce Stockholder Approval of Merger

Mar 12, 2025, 4:01 PM EDT - 8 months ago

Kalaris and AlloVir Announce Stockholder Approval of Merger

ALLOVIR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AlloVir, Inc. - ALVR

Feb 10, 2025, 12:20 PM EST - 9 months ago

ALLOVIR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AlloVir, Inc. - ALVR

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EMKR and ALVR on Behalf of Shareholders

Nov 9, 2024, 10:26 AM EST - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EMKR and ALVR on Behalf of Shareholders

EMKR

AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina

Nov 8, 2024, 6:00 AM EST - 1 year ago

AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina

Kuehn Law Encourages Investors of AlloVir, Inc. to Contact Law Firm

Sep 16, 2024, 11:16 AM EDT - 1 year ago

Kuehn Law Encourages Investors of AlloVir, Inc. to Contact Law Firm

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Mar 19, 2024, 7:00 AM EDT - 1 year ago

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Mar 17, 2024, 11:00 PM EDT - 1 year ago

FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

MARCH 19 FINAL DEADLINE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Mar 11, 2024, 7:00 AM EDT - 1 year ago

MARCH 19 FINAL DEADLINE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

INVESTOR DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Mar 9, 2024, 8:00 AM EST - 1 year ago

INVESTOR DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Mar 8, 2024, 3:30 AM EST - 1 year ago

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 19, 2024 in AlloVir, Inc. Lawsuit - ALVR

Mar 7, 2024, 5:45 AM EST - 1 year ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 19, 2024 in AlloVir, Inc. Lawsuit - ALVR

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Mar 7, 2024, 3:30 AM EST - 1 year ago

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

MARCH 19 DEADLINE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Mar 6, 2024, 1:00 PM EST - 1 year ago

MARCH 19 DEADLINE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

IMPORTANT MARCH DEADLINE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Mar 5, 2024, 2:15 PM EST - 1 year ago

IMPORTANT MARCH DEADLINE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

IMPORTANT MARCH DEADLINE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses to Contact the Firm

Mar 4, 2024, 3:00 PM EST - 1 year ago

IMPORTANT MARCH DEADLINE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses to Contact the Firm

ALLOVIR INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options

Feb 9, 2024, 10:45 AM EST - 1 year ago

ALLOVIR INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options

IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Feb 6, 2024, 8:00 AM EST - 1 year ago

IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Jan 26, 2024, 8:00 AM EST - 1 year ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

11thestate
11thestate Oct. 22 at 12:10 PM
$ALVR has agreed to a $1M settlement to resolve claims that it misled investors about the effectiveness and prospects of its lead product, Posoleucel. Who’s eligible? Anyone who purchased $ALVR shares between January 11, 2023, and December 21, 2023. Do I need to sell my shares to qualify? No — you are eligible whether you sold your shares or still hold them. How much is the payout? The payout per share is $0.03 — but if only ~25% of eligible investors file, the effective payout could increase to $0.12. Can I still file? Yes — claims are currently being accepted, including late claims (claim deadline pending court approval). When do payouts happen? Typically within 8–12 months after court approval of the settlement. To file your claim: https://11th.com/cases/allovir-investor-settlement?utm_source=stocktwits&utm_medium=referral&utm_campaign=faq&utm_content=10222025_1
0 · Reply
11thestate
11thestate Oct. 14 at 11:52 AM
$ALVR has agreed to a $1.X million settlement to resolve claims that it misled investors about the effectiveness of its lead drug candidate, Posoleucel, and the likelihood of success for its Phase 3 trials. Who’s eligible? Anyone who purchased $ALVR shares between January 11, 2023 and December 21, 2023. Do I need to sell my shares to qualify? No — you are eligible whether you sold your shares or still hold them. How much is the payout? The payout per share is $0.03 — but if only ~25% of eligible investors file, the effective payout could increase to $0.12. Can I still file? Yes — claims are currently being accepted. When do payouts happen? Typically within 8–12 months after court approval of the settlement. To file your claim: https://11th.com/cases/allovir-investor-settlement?utm_source=stocktwits&utm_medium=referral&utm_campaign=faq&utm_content=10142025_1
0 · Reply
GridDrift_33
GridDrift_33 Oct. 2 at 3:15 PM
$ALVR NXXT at $1.94 with P S 4.9x lining for rerate to $5.5 once margins flip and EPS prints
0 · Reply
11thestate
11thestate Sep. 24 at 12:52 PM
$ALVR has agreed to settle with investors by paying $1 million to resolve claims that it misled them about the effectiveness of its lead product, Posoleucel. Who’s eligible? Anyone who purchased $ALVR shares between January 11, 2023 and December 21, 2023. Do I need to sell my shares to qualify? No — you are eligible whether you sold your shares or still hold them. How much is the payout? The payout per share is $0.03 — but if only ~25% of eligible investors file, the effective payout could increase to $0.12. Can I still file? Yes — late claims are currently being accepted. When do payouts happen? Typically within 8–12 months after court approval of the settlement. To file your claim: https://11th.com/cases/allovir-investor-settlement?utm_source=stocktwits&utm_medium=referral&utm_campaign=faq&utm_content=09242025_1
0 · Reply
topstockalerts
topstockalerts Sep. 16 at 6:48 PM
$ALVR setting up nicely.. 👀
0 · Reply
11thestate
11thestate Sep. 11 at 10:36 PM
$ALVR has agreed to settle with investors by paying $1 million to resolve claims that it misled them about the effectiveness of its lead product, Posoleucel. Who’s eligible? Anyone who purchased $ALVR shares between January 11, 2023 and December 21, 2023. Do I need to sell my shares to qualify? No — you are eligible whether you sold your shares or still hold them. How much is the payout? The payout per share is $0.03 — but if only ~25% of eligible investors file, the effective payout could increase to $0.12. Can I still file? Yes — late claims are currently being accepted. When do payouts happen? Typically within 8–12 months after court approval of the settlement. To file your claim: https://11th.com/cases/allovir-investor-settlement?utm_source=stocktwits&utm_medium=referral&utm_campaign=faq&utm_content=09112025_1
0 · Reply
11thestate
11thestate Sep. 4 at 2:39 AM
$ALVR investors, if you follow us, you already knew about it. This is the good news you needed about $ALVR today. Go check it out: https://11th.com/cases/allovir-investor-settlement?utm_source=stocktwits&utm_medium=referral&utm_campaign=stlm&utm_content=09032025_1 #AlloVir #ALVR
0 · Reply
11thestate
11thestate Aug. 26 at 3:55 AM
$ALVR has reached a $1 million settlement with investors to resolve claims that it misled them about the effectiveness of its lead product, Posoleucel. Who’s eligible? Anyone who purchased $ALVR shares between January 11, 2023, and December 21, 2023. Do I need to sell my shares to qualify? No — you are eligible whether you sold your shares or still hold them. How much is the payout? The payout per share is $0.03 — but if only ~25% of eligible investors file, the effective payout could increase to $0.12 per share. Can I still file? Yes — claims are currently being accepted. When do payouts happen? Typically within 8–12 months after court approval of the settlement. To file your claim: https://11th.com/cases/allovir-investor-settlement?utm_source=stocktwits&utm_medium=referral&utm_campaign=faq&utm_content=08262025_1
0 · Reply
11thestate
11thestate Aug. 15 at 4:45 AM
#AlloVir has reached a $1M settlement with $ALVR investors over claims that it misled them about the effectiveness of its lead product, Posoleucel. 📅 Class Period: Jan 11, 2023 – Dec 21, 2023 🗓️ Claim Deadline: Aug 19, 2025 If you purchased $ALVR during this period, you may be eligible for compensation here: https://11th.com/cases/allovir-investor-settlement?utm_source=stocktwits&utm_medium=referral&utm_campaign=ddl&utm_content=08152025_7
0 · Reply
11thestate
11thestate Aug. 13 at 10:43 AM
#AlloVir has reached a $1M settlement with $ALVR investors over claims it misled them about the effectiveness of its lead product, Posoleucel. 📅 Class Period: Jan 11, 2023 – Dec 21, 2023 🗓️ Claim Deadline: Aug 19, 2025 If you purchased $ALVR during this period, you may be eligible for compensation here: https://11th.com/cases/allovir-investor-settlement?utm_source=stocktwits&utm_medium=referral&utm_campaign=ddl&utm_content=08122025_1
0 · Reply
11thestate
11thestate Aug. 6 at 5:33 AM
AlloVir has reached a $1M settlement with $ALVR investors over claims that it misled them about the effectiveness of its lead product, Posoleucel. 📅 Class Period: Jan 11, 2023 – Dec 21, 2023 🗓️ Claim Deadline: Aug 19, 2025 If you bought $ALVR during this period, you can file a claim for payment here: https://11th.com/cases/allovir-investor-settlement?utm_source=stocktwits&utm_medium=referral&utm_campaign=ddl&utm_content=08062025_1
0 · Reply
11thestate
11thestate Jul. 28 at 1:12 PM
$ALVR losses? There is a recovery path you can follow. Here’s where to start: https://11th.com/cases/allovir-investor-settlement #AlloVir #ALVR
0 · Reply
11thestate
11thestate Jul. 17 at 11:40 AM
AlloVir has agreed to a $1M settlement with $ALVR investors over claims it misled them about the effectiveness of its lead product, Posoleucel. ⏳ Claim deadline: August 19, 2025 📅 Class Period: January 11, 2023 – December 21, 2023 If you bought $ALVR during that time, you can file a claim for payment here: https://11th.com/cases/allovir-investor-settlement
0 · Reply
11thestate
11thestate Jul. 9 at 8:15 PM
🧬 AlloVir has agreed to a $1M settlement with $ALVR investors over claims that it misled them about the effectiveness of its lead product, Posoleucel. ⏰ Claim deadline is August 19, 2025. If you bought $ALVR between January 11, 2023, and December 21, 2023, you can file a claim for payment here: https://11th.com/cases/allovir-investor-settlement
0 · Reply
11thestate
11thestate Jul. 1 at 8:21 PM
#AlloVir has agreed to settle $1M with $ALVR investors over claims that it misled them about the effectiveness of its lead product, Posoleucel. The deadline to file a claim is coming up: August 19, 2025. If you bought $ALVR between January 11, 2023, and December 21, 2023, you can file a claim for payment: https://11th.com/cases/allovir-investor-settlement
0 · Reply
11thestate
11thestate Jun. 23 at 8:18 PM
$ALVR investors, if you follow us, you already knew about it. Here’s the good news you’ve been waiting for. Go check it out. #AlloVir $ALVR https://11th.com/cases/allovir-investor-settlement
0 · Reply
11thestate
11thestate Jun. 12 at 10:36 PM
Don’t forget that if you held $ALVR, there’s a significant settlement you can also claim. Consider it the dividend #AlloVir never paid. https://11th.com/cases/allovir-investor-settlement
0 · Reply
11thestate
11thestate Jun. 4 at 12:04 PM
Don’t forget that if you held $ALVR, there’s a significant settlement you can also claim. Consider it the dividend #AlloVir never paid. https://11th.com/cases/allovir-investor-settlement
0 · Reply
11thestate
11thestate May. 27 at 10:35 AM
$ALVR investors, if you follow us, you already knew about it. This is the good news you needed about $ALVR today. Go check it out. #AlloVir #ALVR https://11th.com/cases/allovir-investor-settlement
0 · Reply
11thestate
11thestate May. 20 at 4:29 PM
$ALVR agreed to a $1M settlement with investors over claims it made false or misleading statements about its business. Who’s eligible? Anyone who bought and held $ALVR stock through December 21, 2023. Do I need to sell to qualify? No — you're eligible if you bought during that period, even if you still hold the shares. How much is the payout? Estimated at $0.03 per share — but if only 25% of eligible investors file, it could go up to $0.12 per share. Can I still file? Yes — claims are currently being accepted. When do payouts happen? Usually 4–9 months after the court grants final approval. To file your claim: https://11th.com/cases/allovir-investor-settlement
0 · Reply
11thestate
11thestate May. 12 at 11:24 AM
$ALVR agreed to a $1M settlement with investors over claims it misled them about the effectiveness of its lead treatment, Posoleucel, during failed Phase 3 trials. Who’s eligible? Anyone who bought and held $ALVR stock between January 11, 2023 and December 21, 2023. Do I need to sell my shares to qualify? No — you're eligible if you purchased during that period, regardless of whether you sold or still hold. How much is the payout? Estimated at $0.03 per share, depending on how many investors file. Can I still file? Yes — late claims are currently being accepted, subject to court approval. When do payouts happen? Usually 8–12 months after final approval. To file your claim: https://11th.com/cases/allovir-investor-settlement
0 · Reply
youspeaktome
youspeaktome May. 8 at 7:09 PM
$ALVR $KLRS Doing some work here and this should be valued at 30% of cash. Their drug is still in Phase 1 very early trials
0 · Reply